Suchergebnisse - "Voorhees, Peter M"

PubPharm (26)

1

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN) : final analysis of an open-label, randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2023

von Voorhees, P. | Sborov, D. | Laubach, J. | +25

CommentIn: Lancet Haematol. 2023 Oct;10(10):e788-e789. - PMID 37793762

2

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma : Findings from the MASTER and GRIFFIN Trials

enthalten in: Transplantation and cellular therapy | 2023

von Chhabra, S. | Callander, N. | Watts, N. | +34

3

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma : Analysis of vascular thrombotic events in the GRIFFIN study

enthalten in: British journal of haematology | 2022

von Sborov, D. | Baljevic, M. | Reeves, B. | +18

4

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

enthalten in: The New England journal of medicine | 2022

von Richardson, P. | Jacobus, S. | Weller, E. | +125

CommentIn: Expert Rev Hematol. 2023 Jul-Dec;16(8):561-563. - PMID 37334674

5

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211) : primary analysis of a randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2021

von Usmani, S. | Hoering, A. | Ailawadhi, S. | +15

CommentIn: Lancet Haematol. 2021 Jan;8(1):e4-e6. - PMID 33357481

6

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

enthalten in: BMC cancer | 2020

von Fonseca, R. | Usmani, S. | Mehra, M. | +9

7

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

enthalten in: BMC cancer | 2020

von Fonseca, R. | Usmani, S. | Mehra, M. | +9

8

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

enthalten in: BMC cancer | 2020

von Fonseca, R. | Usmani, S. | Mehra, M. | +9

9

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma : the GRIFFIN trial

enthalten in: Blood | 2020

von Voorhees, P. | Kaufman, J. | Laubach, J. | +26

CommentIn: Blood. 2020 Aug 20;136(8):917-918. - PMID 32818244

10

Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2017

von Voorhees, P. | Gasparetto, C. | Moore, D. | +3